Clinical Trial Update: Safety and Tolerability Study of 68Ga/177Lu-BRP-020063 in Advanced Solid Tumors [EARLY_Phase 1]

View source ↗

Summary

An early-phase, safety and tolerability study of BRP-020063 labeled with gallium-68 and lutetium-177 in advanced solid tumors, including urothelial carcinoma; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• BRP-020063 (BRP-020063)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Urothelial Carcinoma (UC) | EARLY_Phase 1 | Status: NOT_YET_RECRUITING